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Abstract
The interAdapt R package is designed to be used by statisticians and clinical investigators to
plan randomized trials. It can be used to determine if certain adaptive designs offer tangible benefits
compared to standard designs, in the context of investigators’ specific trial goals and constraints.
Specifically, interAdapt compares the performance of trial designs with adaptive enrollment criteria
versus standard (non-adaptive) group sequential trial designs. Performance is compared in terms of
power, expected trial duration, and expected sample size. Users can either work directly in the R
console, or with a user-friendly shiny application that requires no programming experience. Several
added features are available when using the shiny application. For example, the application allows
users to immediately download the results of the performance comparison as a csv-table, or as a
printable, html-based report.
Introduction
Group sequential, randomized trial designs involve rules for early stopping of an entire trial based on
analyses of accrued data. Such early stopping could occur if there is strong evidence early in the trial
of benefits or harms of the new treatment being studied. Adaptive enrichment designs involve rules
for restricting enrollment criteria based on data accrued in an ongoing trial. For example, enrollment
could be stopped for a certain subpopulation if there is strong early evidence that the treatment does
not benefit that group. We focus on the class of designs introduced by Rosenblum et al. [2013], which
combines features of both group sequential and adaptive enrichment designs. For conciseness, we refer
to designs in this class as “adaptive designs.” These are contrasted with “standard designs,” defined
to be group sequential designs where the enrollment criteria cannot be changed during the trial (except
that the entire trial may be stopped early for efficacy or futility).
We introduce the interAdapt R package, a user friendly set of tools for exploring certain types of
adaptive enrichment designs. The package contains a densely featured shiny application, ideal for users
with little to no R programming experience, as well as an R function (compute_design_performance)
which provides the same core computational functionality that underlies the shiny application. Several
input parameters are available to allow the user to describe the context of his/her trial. Computations
for generating output typically require less than 15 seconds on a standard commercial laptop.
Several added features are available when using the shiny application, as opposed to the command
line function. For example, users can upload data from previous studies, and the application will au-
tomatically compute the relevant parameters for the trial being planned. Once entered, the full set of
input parameters can be saved to the user’s computer for use in future sessions. Results of the design
comparisons can be immediately downloaded in the form of either csv-tables, or printable, html-based
reports. The shiny application is also hosted on the RStudio webserver, and can be accessed online
without installing the R programming language.
To demonstrate our software, we consider the problem of planning a Phase III trial for a new surgical
treatment of stroke, which is considered by Rosenblum et al. [2013]. The new treatment is called
Minimally-Invasive Surgery Plus rt-PA for Intracerebral Hemorrhage (MISTIE), and is described in
detail by Morgan et al. [2008]. Previous trials had almost exclusively enrolled participants with little or
no intraventricular hemorrhage (IVH) at baseline (referred to as small IVH participants). However, it
was conjectured that the treatment may also benefit participants with large IVH volume at baseline. The
goal of the Phase III trial being planned was to determine whether MISTIE is effective for the combined
population of those with small or large IVH, and, if not, to determine whether MISTIE is effective for
the small IVH population (for whom there was greater prior evidence). A standard trial design may
be inefficient at simultaneously answering these questions. An alternative is to use an adaptive trial
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design that first recruits from the combined population, and then decides whether to restrict enrollment
based on results from interim analyses. Though we focus on this stroke trial application throughout, our
software tool can be applied in many disease areas.
In Section 1, we formally define the hypothesis testing problem to be addressed by the different
trial designs. In Section 2, we compare our software to the most similar, currently available software,
AptivSolutions ADDPLAN PE (Participant Enrichment), and the asd R package. In Section 3, we
describe how to install interAdapt on a personal computer, run the shiny application locally, use the
package functionality in the command line, and access the application online through a web browser.
Section 4 describes the inputs available when using interAdapt, and discusses the interpretation of the
package’s output. In Section 5, we present an example demonstrating how an adaptive design is created
and analyzed with interAdapt.
1 Problem description
We consider the problem of designing a randomized trial to test whether a new treatment is superior
to control, for a given population (e.g., those with intracerebral hemorrhage in the MISTIE example).
Consider the case where we have two subpopulations, referred to as subpopulation 1 and subpopulation
2, which partition the overall population of interest. These must be specified before the trial starts, and
be defined in terms of participant attributes measured at baseline (e.g., having a high initial severity of
disease or a certain biomarker value). We focus on situations where there is suggestive, prior evidence that
the treatment may be more likely to benefit subpopulation 1. In the MISTIE trial example, subpopulation
1 refers to small IVH participants, and subpopulation 2 refers to large IVH participants. Let pi1 and pi2
denote the proportion of the population in subpopulations 1 and 2, respectively.
Both the adaptive and standard designs discussed here involve enrollment over time, and include
predetermined rules for stopping the trial early based on interim analyses. Each trial consists of K
stages, indexed by k. In stages where both subpopulations are enrolled, we assume that the proportion
of newly recruited participants in each subpopulation s ∈ {1, 2} is equal to the corresponding population
proportion pis.
For a given design, let nk denote the maximum number of participants to be enrolled during stage k.
The number enrolled during stage k will be less than nk if the trial is entirely stopped before stage k (so
that no participants are enrolled in stage k) or if in the adaptive design enrollment is restricted to only
subpopulation 1 before stage k (as described in Section 1.4). For each subpopulation s ∈ {1, 2} and stage
k, let Ns,k denote the maximum cumulative number of subpopulation s participants who have enrolled
by the end of stage k. Let NC,k denote the maximum cumulative number of enrolled participants from
the combined population by the end of stage k, i.e., NC,k = N1,k +N2,k. The sample sizes will generally
differ for different designs.
Let Yi,k be a binary outcome variable for the i
th participant recruited in stage k, where Yi,k = 1
indicates a successful outcome. Let Ti,k be an indicator of the i
th participant recruited in stage k being
assigned to the treatment. We assume for each participant that there is an equal probability of being
assigned to treatment (Ti,k = 1) or control (Ti,k = 0), independent of the participant’s subpopulation.
We also assume outcomes are observed very soon after enrollment, so that all outcome data is available
from currently enrolled participants at each interim analysis.
For subpopulation 1, denote the probability of a successful outcome under treatment as p1t, and the
probability of a successful outcome under control as p1c. Similarly, for subpopulation 2, let p2t denote
the probability of a success under treatment, and p2c denote the probability of a success under control.
We assume each of p1c, p1t, p2c, p2t is in the interval (0, 1). We define the true average treatment effect for
a given population to be the difference in the probability of a successful outcome comparing treatment
versus control.
In the remainder of this section we give an overview of the relevant concepts needed to understand
and use interAdapt. A more detailed discussion of the theoretical context, and of the efficacy boundary
calculation procedure, is provided by Rosenblum et al. [2013].
1.1 Hypotheses
We focus on testing the null hypothesis that, on average, the treatment is no better than control for
subpopulation 1, and the analogous null hypothesis for the combined population. Simultaneous testing
of null hypotheses for these two populations was also the goal for the two-stage, adaptive enrichment
designs of Wang et al. [2007]. We define our two null hypotheses, respectively, as
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• H01: p1t − p1c ≤ 0;
• H0C : pi1(p1t − p1c) + pi2(p2t − p2c) ≤ 0.
interAdapt compares different designs for testing these null hypotheses. An adaptive design testing
both null hypotheses (denoted AD) is compared to two standard designs. The first standard design,
denoted SC, enrolls the combined population and only tests H0C . The second standard design, denoted
SS, only enrolls subpopulation 1 and tests H01. All three trial designs consist of K stages; the decision to
entirely stop the trial early can be made at the end of any stage, based on a preplanned rule. The trials
differ in that SC and SS never change their enrollment criteria, while AD may switch from enrolling
the combined population to enrolling only participants from subpopulation 1.
The standard designs discussed here are not identical to those discussed in Section 6.1 of [Rosenblum
et al., 2013], which test both hypotheses simultaneously. Implementing standard designs such as those
discussed in [Rosenblum et al., 2013] into the interAdapt software is an area of future research.
Though it is not of primary interest, we occasionally refer below to the global null hypothesis, defined
to be that p1t − p1c = p2t − p2c = 0, i.e., zero mean treatment effect in both subpopulations.
1.2 Test statistics
Three (cumulative) z-statistics are computed at the end of each stage k. The first is based on all enrolled
participants in the combined population, the second is based on all enrolled participants in subpopulation
1, and the third is based on all enrolled participants in subpopulation 2. Each z-statistic is a standardized
difference in sample means, comparing outcomes in the treatment arm versus the control arm. Let ZC,k
denote the z-statistic for the combined population at the end of stage k, which takes the following form:
ZC,k =
[∑k
k′=1
∑nk′
i=1 Yi,k′Ti,k′∑k
k′=1
∑nk′
i=1 Ti,k′
−
∑k
k′=1
∑nk′
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
−1/2
The term in square brackets is the difference in sample means between the treatment and control
groups. The term in curly braces is the variance of this difference in sample means. ZC,k is only computed
at stage k if the combined population has been enrolled up through the end of stage k (otherwise it is
undefined). Our designs never use ZC,k after stages where the combined population has stopped being
enrolled. Let Z1,k and Z2,k denote analogous z-statistics restricted to participants in subpopulation 1
and subpopulation 2, respectively. These are formally defined in [Rosenblum et al., 2013].
1.3 Type I error control
The familywise (also called study-wide) Type I error rate is the probability of rejecting one or more true
null hypotheses. For a given design, we say that the familywise Type I error rate is strongly controlled
at level α if for any values of p1c, p1t, p2c, p2t (assuming each is in the interval (0, 1)), the probability of
rejecting at least one true null hypothesis (among H0C , H01) is at most α. To be precise, we mean such
strong control holds asymptotically, as sample sizes in all stages go to infinity, as formally defined by
Rosenblum et al. [2013]. For all three designs, AD, SC, and SS, we require the familywise Type I error
rate to be strongly controlled at level α. Since the two standard designs SS and SC each only test a
single null hypothesis, the familywise Type I error rate for each design is equal to the Type I error rate
for the corresponding, single hypothesis test.
1.4 Decision rules for early stopping and for modifying enrollment criteria
The decision rules for the standard design SC consist of efficacy and futility boundaries for H0C , based
on the statistics ZC,k. At the end of each stage k, the test statistic ZC,k is calculated. If ZC,k is above
the efficacy boundary for stage k, the design SC rejects H0C and stops the trial. If ZC,k is between the
efficacy and futility boundaries for stage k, the trial is continued through the next stage (unless the last
stage k = K has been completed). If ZC,k is below the futility boundary for stage k, the design SC stops
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the trial and fails to reject H0C . interAdapt makes the simplification that the number of participants
nk enrolled in each stage of SC is a constant, denoted nSC , that the user can set.
The efficacy boundaries for SC are set to be proportional to those described by Wang and Tsiatis
(1987). Specifically, the efficacy boundary for the kth stage is set to eSC(NC,k/NC,K)
δ, where K is
the total number of stages, δ is a constant in the range [−.5, .5], and eSC is the constant computed by
interAdapt to ensure the familywise Type I error rate is at most α. Since nk is set equal to nSC for all
values of k, the maximum cumulative sample size NC,k reduces to
∑k
k′=1 nSC = knSC , and the boundary
at stage k reduces to the simpler form eSC(k/K)
δ. By default, interAdapt sets δ to be −0.5, which
corresponds to the efficacy boundaries of O’Brien and Fleming [1979].
In order to calculate eSC , interAdapt makes use of the fact that the random vector of test statis-
tics (ZC,1, ZC,2, . . . ZC,K) converges asymptotically to a multivariate normal distribution with a known
covariance structure [Jennison and Turnbull, 1999]. Using the mvtnorm package [Genz et al., 2013] in
R to evaluate the multivariate normal distribution function, interAdapt computes the proportionality
constant eSC to ensure the probability of ZC,k exceeding eSC(NC,k/NC,K)
δ at one or more stages k is
less than or equal to α at the global null hypothesis defined in Section 1.1.
In SC, as well as in SS and AD, interAdapt uses non-binding futility boundaries. That is, the fam-
ilywise Type I error rate is controlled at level α regardless of whether the futility boundaries are adhered
to or ignored. The motivation is that regulatory agencies may prefer non-binding futility boundaries to
ensure Type I error control even if a decision is made to continue the trial despite a futility boundary
being crossed.
In calculations of power, expected sample size, and expected trial duration, interAdapt assumes
futility boundaries are adhered to.
Futility boundaries for the first K − 1 stages of SC are set equal to fSC(NC,k/NC,K)δ, where fSC
is a proportionality constant set by the user. By default, the constant fSC is set to be negative (so the
trial is only stopped for futility if the z-statistic is below the corresponding negative threshold), although
this is not required. In the Kth stage of the trial, interAdapt sets the futility boundary to be equal to
the efficacy boundary. This ensures that the final z-statistic ZC,K crosses either the efficacy boundary
or the futility boundary.
The decision boundaries for the design SS are defined analogously as for the design SC, except
using z-statistics Z1,k. interAdapt makes the simplification that the number of participants nk enrolled
in each stage k of SS is constant, denoted by nSS , and set by the user. The efficacy boundary for
the kth stage is set equal to eSS(N1,k/N1,K)
δ, where eSS is the constant computed by interAdapt to
ensure the Type I error rate is at most α. The first K − 1 futility boundaries for H01 are set equal to
fSS(N1,k/N1,K)
δ, where fSS is a constant that can be set by the user. The futility boundary in stage K
is set equal to the final efficacy boundary in stage K.
Consider the adaptive design AD. interAdapt allows the user to a priori specify a final stage at which
there will be a test of the null hypothesis for the combined population, denoted by stage k∗. Regardless
of the results at stage k∗, AD always stops enrolling from subpopulation 2 at the end stage k∗. This
reduces the maximum sample size of AD compared to allowing enrollment from both subpopulations
through the end of the trial. The futility boundaries l2,k are not defined for k > k
∗, since subpopulation 2
is not enrolled after stage k∗. The user may effectively turn off the option described in this paragraph by
setting k∗ = K, the total number of stages; then the combined population may be enrolled throughout
the trial.
For the AD design, the user can specify the following two types of per-stage sample sizes: one for
stages where both subpopulations are enrolled (k ≤ k∗), and one for stages where only participants in
subpopulation 1 are enrolled (k > k∗). We refer to these two sample sizes as n(1) and n(2), respectively.
Because AD simultaneously tests H0C and H01 it has two sets of decision boundaries. For the
kth stage of AD, let uC,k and u1,k denote the efficacy boundaries for H0C and H01, respectively. The
boundaries uC,k are set equal to eAD,C(NC,k/NC,K)
δ for each k ≤ k∗; the boundaries u1,k are set equal to
eAD,1(N1,k/N1,K)
δ for each k ≤ K. The constants eAD,C and eAD,1 are set such that the probability of
rejecting one or more null hypotheses under the global null hypothesis is α (ignoring futility boundaries).
It is proved by Rosenblum et al. [2013] that this strongly controls the familywise Type I error rate at
level α. The algorithm for computing the proportionality constants eAD,C , eAD,1 is described later in
this section.
The boundaries for futility stopping of enrollment from certain population in the AD design, at the
end of stage k, are denoted by l1,k and l2,k. These stopping boundaries are defined relative to the test
statistics Z1,k and Z2,k, respectively. The boundaries l1,k and l2,k are set equal to fAD,1(N1,k/N1,K)
δ
(for k ≤ K) and fAD,2(N2,k/N2,K)δ (for k < k∗), respectively, where fAD,1 and fAD,2 can be set by
4
the user. In stage k∗, the futility boundary l2,k∗ is set to “Inf” (indicating ∞), to reflect that we stop
enrollment in subpopulation 2. At the end of each stage, AD may decide to continue enrolling from the
combined population, enroll only from subpopulation 1 for the remainder of the trial, or stop the trial
entirely. Specific decision rules based on these boundaries for the z-statistics are described below.
As described in [Rosenblum et al., 2013], the decision rule in AD consists of the following steps carried
out at the end of each stage k:
1. (Assess Efficacy) If Z1,k > u1,k, reject H01. If k ≤ k∗ and ZC,k > uC,k, reject H0C . If H01, H0C , or
both are rejected, stop all enrollment and end the trial.
2. (Assess Futility of Entire Trial) Else, if Z1,k ≤ l1,k or if this is the final stage of the trial, stop all
enrollment and end the trial for futility, failing to reject any null hypothesis.
3. (Assess Futility for H0C) Else, if Z2,k ≤ l2,k, or if k ≥ k∗, stop enrollment from subpopulation 2 in
all future stages. In this case, the following steps are iterated at each future stage:
3a. If Z1,k > u1,k, reject H01 and stop all enrollment.
3b. If Z1,k ≤ l1,k or if this is the final stage of the trial, fail to reject any null hypothesis and
stop all enrollment.
3c. Else, continue enrolling from only subpopulation 1. If k < k∗ then pi1n(1) participants
from subpopulation 1 should be enrolled in the next stage. If k ≥ k∗, then n(2) participants from
subpopulation 1 should be enrolled in the next stage. In all future stages, ignore steps 1, 2, 4, and
use steps 3a–3c.
4. (Continue Enrollment from Combined Population) Else, continue by enrolling pi1n
(1) participants
from subpopulation 1 and pi2n
(1) participants from subpopulation 2 for the next stage.
The motivation for Step 2 is that there is assumed to be prior evidence that if the treatment works,
it will work for subpopulation 1. Therefore, if subpopulation 1 is stopped for futility, the whole trial is
stopped. It is an area of future research to consider modifications to this rule, and to incorporate testing
of a null hypothesis for only subpopulation 2.
A consequence of the rule in Step 3 is that Steps 1, 2, and 4 are only carried out for stages k ≤ k∗.
This occurs since Step 3 restricts enrollment to subpopulation 1 if Z2,k ≤ l2,k or k ≥ k∗, and if so runs
Steps 3a–3c through the remainder of the trial.
We next describe the algorithm used by interAdapt to compute the proportionality constants
eAD,C , eAD,1 that define the efficacy boundaries uC,k, u1,k. These are selected to ensure the family-
wise Type I error rate is strongly controlled at level α. By Theorem 5.1 of [Rosenblum et al., 2013],
to guarantee such strong control of the familywise Type I error rate, it suffices to set uC,k, u1,k such
that the familywise Type I error rate is at most α at the global null hypothesis defined in Section 1.1.
The algorithm takes as input the following, which are set by the user as described in Section 4.1.1: the
per-stage sample sizes n(1), n(2), the study-wide (i.e., familywise) Type I error rate α, and a value ac in
the interval [0, 1]. Roughly speaking, ac represents the fraction of the study-wide Type I error α initially
allocated to testing H0C , as described next.
The algorithm temporarily sets eAD,1 =∞ (effectively ruling out rejection of H01) and computes (via
binary search) the smallest value eAD,C such the probability of rejecting H0C is acα under the global
null hypothesis defined in Section 1.1. This defines eAD,C . Next, interAdapt computes the smallest
constant eAD,1 such that the probability of rejecting at least one null hypothesis under the global null
hypothesis is at most α.
All of the above computations use the approximation, based on the multivariate central limit theorem,
that the joint distribution of the z-statistics is multivariate normal with covariance matrix as given, e.g.,
by Jennison and Turnbull [1999], Rosenblum et al. [2013].
2 Related software
The most comparable available software tools are AptivSolutions ADDPLAN PE (Participant Enrich-
ment), and the asd R package [Parsons et al., 2012]. Both have features that our software does not
have. Conversely, there are features of our software that ADDPLAN PE and asd do not have.
ADDPLAN PE is a versatile, commercial software tool that implements many types of adaptive
enrichment designs. One limitation is that the user must a priori designate a particular stage (e.g., stage
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2) at which a change to enrollment may be made, even though there may be large prior uncertainty
as to when sufficient information will have accrued to make such a decision. In contrast, interAdapt
is more flexible, in that one can select designs in which the decision to change enrollment criteria may
occur at any stage (by setting k∗ to the maximum number of stages K). interAdapt implements the
class of designs from [Rosenblum et al., 2013], while ADDPLAN PE does not. However, ADDPLAN
implements a wide variety of other decision rules and testing procedures not available in interAdapt.
Finally, interAdapt is cross-platform and open-source, while ADDPLAN PE is commercial software
that is only compatible with the Windows OS.
The asd package allows R users to generate two-stage adaptive designs, which can be used to combine
phase II and phase III clinical trials into a seamless design [Parsons et al., 2012]. Unlike interAdapt,
the asd package can generate not only adaptive enrichment designs, but also adaptive designs that test
multiple different treatments. Also in asd, decision rules at interim analyses can be based on short-term
outcomes for each subject enrolled, if the long-term outcome is not yet available. However, asd does
not allow more than two stages, unlike interAdapt which allows up to 20 stages (though in practice
fewer stages will probably be used, e.g., 5 stages). asd is an R package, so is cross-platform and open-
source. Using asd requires a working knowledge of R, while the GUI for interAdapt can be run in a
web browser, with little to no interaction with the R console (see Section 3), and so does not require
knowledge of the R language.
3 Running interAdapt
The interAdapt R package contains an interactive web browser application, as well as a command line
function which performs the same computations. The browser application is built on the shiny package
[RStudio and Inc., 2013], with the back-end calculations done in R.
To access the shiny application, interAdapt requires the user’s default web browser to be set to
either Firefox (http://www.mozilla.org) or Chrome (http://www.google.com/chrome/). Users can
then run the application either by installing R and the interAdapt package locally on their computer,
or by simply using Firefox or Google Chrome to view interAdapt online. Both options are free and
quick to set up. However, because the online application will slow down noticeably if accessed by multiple
users simultaneously, we encourage heavy users to install interAdapt locally.
3.1 Running interAdapt over the web
interAdapt is currently hosted on the RStudio webserver, and can be accessed at:
http://spark.rstudio.com/mrosenblum/interAdapt
3.2 Running interAdapt locally
To run interAdapt locally, one must first install the R programming language. R runs on both Windows
& MacOS, is available for download at (http://www.r-project.org/). After downloading and installing
R, activating the R application will open an “R console” window where typed commands are executed
by R. The interAdapt R package can be installed by typing the lines below into the R console, while
connected to the internet. The return key must be pressed after each line of code. The first and third
lines will cause R to give feedback on the installation’s progress, which we do not show here.
install.packages('devtools')
library('devtools')
install_github(username='aaronjfisher',repo='interAdapt',subdir='r_package')
Once interAdapt has been installed, the shiny application can be run without an internet connection
by opening the R console and typing
library('interAdapt')
runInterAdapt()
6
The same calculations can be done directly in the R console, using the compute_design_performance
function. Further details are provided in the interAdapt package documentation, which can be accessed
by typing help(package=interAdapt) into the R console. The function’s arguments are the same as
the parameters available in the shiny application (see Section 4.1). The function’s value contains the
output tables of the shiny application. These tables can be used to generate the plots made by the
application (see Section 4.2).
4 User interface for the shiny application
In this section, and in Section 5, we will generally use the term interAdapt to refer to the interAdapt
shiny application, although the inputs and outputs of the command line interface (see Section 3.2) have
the same interpretation.
Inputs to interAdapt can be entered in the side panel on the left, with outputs shown in the
main panel on the right (Figures 1 and 2). The parameters in the input panel let the user describe
characteristics of their study populations, such as the proportion of participants in each subpopulation.
The user can also input design requirements such as the familywise Type I error rate. Also, the user can
input conjectured rates of success under treatment and control, to determine how well different designs
perform at a given set of such values. Specifically, the user can input values for p1t, p1c, and p2c, and
interAdapt will compare the performance of different designs over a range of values of p2t, as further
described below.
The main panel displays the decision boundaries and trial designs computed by interAdapt to satisfy
the requirements specified by the user (Figure 1). It also compares the performance of the three designs,
AD, SC and SS (Figure 2). Performance is compared in terms of power, expected sample size, and
expected trial duration.
All tables generated by interAdapt can be downloaded as csv files by clicking on the “Download”
button beneath the table. Users can also download a printable, html-based report of the results by
clicking the “Generate Report” button at the bottom of the main panel (Figures 1 and 2). This report
is generated with the knitr package for R [Xie, 2013]. Citations in the report are created using the
knitcitations package [Boettiger, 2013].
4.1 Inputs
Parameters in the input panel are organized into the following two sections: Basic Parameters and
Advanced Parameters. To view the different sets of parameters, click the drop-down menu titled “Show
Basic Parameters.”
Basic Parameters can be entered using either “Batch mode” or “Interactive mode”. In Batch mode,
interAdapt will not analyze the entered parameters until the “Apply” button is pressed. This allows
several parameters to be changed at once without waiting for interAdapt to recalculate the results after
each individual change. In Interactive mode, interAdapt will automatically recalculate the results after
each change, allowing the user to quickly see the effect of changing a single input parameter. Switching
between Batch mode and Interactive mode can be done using the dropdown menu at the top of the Basic
Parameters section. Interactive mode is not available when entering Advanced Parameters.
To save the current set of inputs, click the dropdown menu titled “Show Basic Parameters” and select
“Show All Parameters and Save/Load Option”. You can then save the current parameters as a csv file,
or load a previously saved csv file of inputs (Figure 2). Regardless of whether interAdapt is being run
online or locally, these saved csv files are always stored on the user’s computer.
You may load a 3-column dataset into interAdapt in csv format, e.g., from a previous trial or
study, to use in setting population parameters for simulations of hypothetical, future trials. E.g., if
one is planning a Phase III trial, one might upload Phase II trial data that is already available. The
purpose of this feature is to allow the data generating mechanisms in the interAdapt simulations to
mimic properties of real datasets relevant to the study being planned. interAdapt will compute the
empirical values of pi1, p1c, p1t, p2c, and p2t from the given dataset, and set the corresponding slider
values to match these. The dataset must be structured to have one row for each participant. The first
column must contain binary indicators of subpopulation, where 1 denotes subpopulation 1, and 2 denotes
subpopulation 2. The second column must contain an indicator of the treatment arm (Ti), and the third
column must contain the binary outcome measurement (Yi). The first row of this dataset file is expected
to be a header row of labels, rather than values for the first individual. From this dataset, interAdapt
will calculate pi1, p1c, p1t, p2c, and p2t, and adjust the input sliders accordingly. The user can then
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modify these parameter settings to determine how robust a given design is to differences between what
was observed in previous studies and a hypothetical, future study.
A detailed explanation of each input is given below.
4.1.1 Basic Parameters (with corresponding variables in parentheses, where applicable)
• Subpopulation 1 proportion (pi1): The proportion of the population in subpopulation 1. This is
the subpopulation in which we have prior evidence of a stronger treatment effect.
• Probability outcome = 1 under control, subpopulation 1 (p1c): The probability of a successful
outcome for subpopulation 1 under assignment to the control arm. This is used in estimating
power and expected sample size of each design.
• Probability outcome = 1 under control, subpopulation 2 (p2c): The probability of a successful
outcome for subpopulation 2 under assignment to the control arm. This is used in estimating
power and expected sample size of each design.
• Probability outcome = 1 under treatment for subpopulation 1 (p1t): The probability of a successful
outcome for subpopulation 1 under assignment to the treatment arm. Note that the user does not
specify p2t; instead, interAdapt considers a range of possible values of p2t that can be set through
the Advanced Parameters described below.
• Per stage sample size, combined population, for adaptive design (n(1)): Number of participants
enrolled per stage in AD, whenever both subpopulations are being enrolled.
• Per stage sample size for stages where only subpopulation 1 is enrolled, for adaptive design (n(2)):
The number of participants required for each stage in AD after stage k∗ (only used if k∗ < K).
For stages up to and including stage k∗, the number of participants enrolled from subpopulation 1
is equal to pi1n
(1).
• Alpha (FWER) requirement for all designs (α): The familywise Type I error rate defined in Sec-
tion 1.3.
• Proportion of Alpha allocated to H0C for adaptive design (aC): This is used in the algorithm in
Section 1.4 to construct efficacy boundaries for the design AD.
4.1.2 Advanced Parameters (with corresponding variables in parentheses, where applica-
ble)
• Delta (δ): This parameter is used as the exponent in defining the efficacy and futility boundaries
as described in Section 1.4.
• # of Iterations for simulation: This is the number of simulated trials used to approximate the power,
expected sample size, and expected trial duration. In each simulated trial, z-statistics are simulated
from a multivariate normal distribution (determined by the input parameters). The greater the
number of iterations, the more accurate the simulation results will be. It is our experience that a
simulation with 10,000 iterations takes about 7-15 seconds on a commercial laptop.
• Time limit for simulation, in seconds: If the simulation time exceeds this threshold, calculations
will stop and the user will get an error message saying that the application has “reached CPU time
limit”. To avoid this, either the number of iterations can be reduced, or the time limit for the
simulation can be extended. interAdapt does not allow for the time limit to exceed 90 seconds
in the online version; there is no such restriction on the local version.
• Total number of stages (K): The total number of stages, which is used in each type of design. The
maximum allowed number of stages is 20.
• Last stage subpopulation 2 is enrolled under adaptive design (k∗): In the adaptive design, no
participants from subpopulation 2 are enrolled after stage k∗.
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• Participants enrolled per year from combined population: This is the assumed enrollment rate (per
year) for the combined population. It impacts the expected duration of the different trial designs.
The enrollment rates for subpopulations 1 and 2 are assumed to equal the combined population
enrollment rate multiplied by pi1 and pi2, respectively. I.e., enrollment rates are proportional to the
relative sizes of the subpopulations. This reflects the reality that enrollment will likely be slower
for smaller subpopulations. Active enrollment from one subpopulation is assumed to have no effect
on the enrollment rate in the other subpopulation. This implies that each stage of the AD design
up to and including stage k∗ takes the same amount of time to complete, regardless of whether
enrollment stops for subpopulation 2. Also, each stage after k∗ takes the same amount of time to
complete.
• Per stage sample size for standard group sequential design (SC) enrolling combined pop. (nSC):
The number of participants enrolled in each stage for SC.
• Per stage sample size for standard group sequential design (SS) enrolling only subpop. 1 (nSS):
The number of participants enrolled in each stage for SS.
• Stopping boundary proportionality constant for subpopulation 2 enrollment for adaptive design
(fAD,2): This is used to calculate the futility boundaries (l2,k) for the z-statistics calculated in
subpopulation 2 (Z2,k) as defined in Section 1.4.
• H01 futility boundary proportionality constant for the adaptive design (fAD,1): This is used to
calculate the futility boundaries (l1,k) for the z-statistics calculated in subpopulation 1 (Z1,k) as
defined in Section 1.4.
• H0C futility boundary proportionality constant for the standard design (fSC): This is used to
calculate the futility boundaries for H0C in SC as defined in Section 1.4.
• H01 futility boundary proportionality constant for the standard design (fSS): This is used to
calculate the futility boundaries for H01 in SS as defined in Section 1.4.
• Lowest value to plot for treatment effect in subpopulation 2: interAdapt does simulations under
a range of treatment effect sizes p2t − p2c for subpopulation 2. This sets the lower bound for this
range. This effectively sets the lower bound for p2t, since p2c is set by the user as a Basic parameter.
• Greatest value to plot for treatment effect in subpopulation 2: interAdapt does simulations under
a range of treatment effect sizes p2t − p2c for subpopulation 2. This sets the upper bound for this
range.
4.2 Outputs
The output panel on the right side of the user interface is split into the following three sections: “About
interAdapt”, “Designs”, and “Performance.” Users can navigate between these sections using the radio
buttons at the top of the panel. The About interAdapt section gives a brief introduction to the software,
and a link to the full software documentation. The Designs section describes the design parameters for
each of the three trials: SC, SS, and AD. This includes the efficacy and futility boundaries, and the
maximum cumulative number of participants enrolled by the end of each stage (under no early stopping).
The Performance section compares the three designs in terms of their power, expected sample size, and
expected duration.
4.2.1 Designs
The Designs section gives design features that result from the user’s inputs. Tabs at the top of the page
can be used to navigate between the different designs. Each of the first three tabs corresponds to one of
the designs, and the fourth tab shows all three together.
In the “Adaptive” tab, the table at the bottom of the page shows the maximum cumulative number of
participants enrolled by the end of each stage for the design AD. This is broken down by subpopulation.
For each stage k, the table also gives efficacy boundaries for Z1,k and ZC,k, and futility boundaries
for Z1,k and Z2,k. Because AD stops enrolling subpopulation 2 after stage k
∗, futility boundaries l2,k
(for statistics Z2,k) in stages k > k
∗ are not given, and l2,k∗ is set to “Inf” (indicating ∞). Efficacy
boundaries for ZC,k are not given for stages k > k
∗ since by construction (see Section 1.4) the AD design
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does not test H0C after stage k
∗. (It is an area of future research to consider designs that continue to
test H0C even after enrollment for subpopulation 2 has stopped.) A plot at the top of the page displays
the efficacy and futility boundaries over all stages of the trial.
The two tabs for the standard designs SC and SS have a comparable layout to that for AD. Note
that the efficacy boundaries for SS and SC are identical. This is because the efficacy boundaries for SC
and SS are both proportional to (k/K)δ, with proportionality constants set to achieve Type I error α,
which leads to identical proportionality constants for SC and SS.
The final tab combines the tables from the first three tabs, and omits plots of the decision boundaries.
4.2.2 Performance output
interAdapt displays the performance of each of the three designs in terms of three metrics: power,
expected sample size, and expected duration. These metrics all depend, among other things, on the
true treatment effect in each subpopulation. A treatment effect for subpopulation 1 can be specified
in the Basic Parameters section, and a range of values for the treatment effect in subpopulation 2 can
be specified in the Advanced Parameters section. interAdapt calculates performance metrics (using
simulations as described in the section on Advanced Parameters) for the specified range of treatment
effects, and generates plots of each metric versus the treatment effect in subpopulation 2. The plot
showing each metric can be accessed via the tabs at the top of the page. The table at the bottom of the
Performance section shows all three metrics, with each column of the table denoting a different treatment
effect in subpopulation 2.
The power plot shows the power of AD to reject H0C , to reject H01, and to reject at least one of H0C
or H01. Since the standard design SC only tests H0C , interAdapt only shows its power to reject H0C .
Similarly, interAdapt only shows the power of SS to reject H01. The power of SS is constant with
respect to the true treatment effect in subpopulation 2. This is as expected, since SS does not enroll
any participants from subpopulation 2.
For the standard designs SC and SS, the expected duration is proportional to the expected sample
size. However, for the AD design, this does not hold; this is because the total trial duration is not
necessarily proportional to the total sample size. E.g., stopping subpopulation 2 will reduce the sample
size but not necessarily reduce the trial duration if subpopulation 1 is not stopped.
5 Example of entering input and interpreting output
The default inputs to interAdapt come from the motivating example of planning the MISTIE Phase
III trial. We next summarize the design goals of the investigators, based on [Rosenblum et al., 2013].
The MISTIE III trial aims to assess a new surgical treatment for stroke. The primary outcome is based
on each participant’s disability score on the modified Rankin Scale (mRS). A successful outcome was
defined as a mRS score less than or equal to 3.
At the time of planning the Phase III MISTIE trial, the previous Phase II trial had only enrolled
participants with little or no intraventricular hemorrhage (IVH). More specifically, participants had been
categorized as “small IVH” if their IVH volume was less than 10ml, and did not require a catheter for
intracranial pressure monitoring. Otherwise, participants were classified as “large IVH.” The Phase
II trial only recruited small IVH participants, and yielded a treatment effect estimate of 12.1% [95%
CI: (-2.7%, 26.9%)]. The investigators thought that the treatment could also be effective in large IVH
participants, but very little data was available to assess this. We refer to those with small IVH as
subpopulation 1, since there was more prior evidence of treatment efficacy in this subpopulation; those
with large IVH are subpopulation 2.
The study designers focused on the following three scenarios of special interest:
(a) The average treatment effect (on the risk difference scale) is 12.5% for both small and large IVH
participants;
(b) The average treatment effect is 12.5% for small IVH participants, and zero for large IVH participants;
(c) The treatment effect is zero for both subpopulations.
The goals were as follows:
(i) At least 80% power for testing H0C in scenario (a);
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(ii) At least 80% power for testing H01 in scenario (b);
(iii) Familywise Type I error rate (α) of 0.025.
Furthermore, the familywise Type I error rate was to be strongly controlled at level 0.025.
Based on prior research by Hanley [2012], the proportion of participants with small IVH (pi1) was
projected to be 0.33, the probability of a positive outcome under control was projected to be 0.25 for
small IVH participants (p1c), and the probability of a positive outcome under control was projected to
be 0.2 for large IVH participants (p2c). If the true average treatment effect in subpopulation 1 is 12.5%,
then the probability of a positive outcome under treatment for participants in subpopulation 1 (p1t) is
projected to be 12.5%+25%=37.5%.
Parameters for the adaptive design AD were computed to achieve all three goals (i)-(iii), as fully
described by [Rosenblum et al., 2013]. The corresponding standard designs, used for comparison, only
had to satisfy subsets of these goals. This is to show the cost of achieving all three goals (since the
adaptive design generally requires greater expected sample size, in return for achieving all three goals
instead of a subset of the goals). The standard design SC was set to achieve goals (i) and (iii), and the
standard design SS was set to achieve (ii) and (iii). Recall that interAdapt allows the user to specify a
range of treatment values for subpopulation 2, and will display the power of the trial designs across this
range. By default, interAdapt sets the range of values for the mean treatment effect in subpopulation
2 to be [-0.2, 0.2]. This includes scenarios (a) and (b) since in scenario (a) the mean treatment effect in
subpopulation 2 is 0.125, and in scenario (b) the mean treatment effect is 0.
The remaining default input parameters for the AD design are based on the adaptive enrichment
design in Section 5.2 of [Rosenblum et al., 2013]. They constructed this design by first setting K = 5 and
δ = −.5, and then searching over a large class of parameter values with the goal of minimizing the average
expected sample size over scenarios (a)-(c), while still achieving goals (i)-(iii). They found a minimum
average expected sample size at k∗ = 3, n(1) = 280, n(2) = 148, aC = .09, and fAD,2 = fAD,1 = 0.
Now we turn to the output of interAdapt that results from the default parameters, and show that
each of the three designs achieves its corresponding goals. In the power plot, we see that AD has 80%
power to reject H0C in scenario (a), and 80% power to reject H01 in scenario (b). SC has 80% power to
reject H0C in scenario (a), and SS has 80% power to reject H01 in scenario (b) (Figure 2). Although it
is not shown, the familywise Type I error rate is at most .025, as this was the specified value of α input
to interAdapt, and the designs are guaranteed to strongly control the familywise Type I error rate at
level α by Theorem 5.1 of [Rosenblum et al., 2013].
Summary
We described the interAdapt R package and shiny application for designing and simulating trials
with adaptive enrollment criteria. We provided an overview of the theoretical problem the application
addresses, and gave an explanation of the application’s inputs and outputs.
Current limitations of the software include that the outcome is assumed to be binary. We also cur-
rently only consider the case where outcomes are measured without delay, immediately after participants
are enrolled. Relaxing both of these requirements is a goal of future work.
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Figure 1: Designs Screenshot: Inputs can be entered in the side panel on the left, with results visible in
the main panel on the right. The drop down menus at the top of the side panel can be used to navigate
different interfaces to input parameters. Here we show the “Basic parameter” inputs, in “Batch mode,”
where the Apply button must be pressed to update the results in the main panel. The radio buttons
at the top of the main panel can be used to navigate between design outputs describing the decision
rules for each trial, and performance summaries for each trial. In this figure we show the design for the
adaptive trial (AD), based on the default input parameters. Boundaries for the z-statistics Z1,k, Z2,k
and ZC,k are shown both in the plot, and in the table. The table also contains information on how many
participants are enrolled in each stage. The scroll bar on the right of the web browser has been cropped
out of this figure for the sake of increased screenshot resolution.
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Figure 2: Performance Screenshot: Here the main panel shows performance output based on the default
parameter inputs. The tabs at the top of the Performance section can be used to navigate between
displays of power, expected sample size, and expected trial duration for all three designs. In the side
panel, we show the interface for saving and loading sets of parameters (section 4.1). Users can save the
current set of inputs, load a previously used set of inputs, or upload a datafile containing results from
a previous trial. If results from a previous trial are uploaded, interAdapt will automatically compute
relevant input parameters based on this file. Additional input parameters in the side panel are available
by scrolling down. As in Figure 1, the scroll bar on the right of the web browser has been cropped out
of this figure for the sake of increased screenshot resolution.
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